LifePlan Financial LLC Invests $255,000 in Pfizer Inc. (NYSE:PFE)

LifePlan Financial LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,864 shares of the biopharmaceutical company’s stock, valued at approximately $255,000.

Other large investors have also added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its stake in Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. Brookstone Capital Management grew its stake in Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the last quarter. ETF Store Inc. grew its stake in Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares during the last quarter. Farmers Trust Co. grew its stake in Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after purchasing an additional 4,410 shares during the last quarter. Finally, Wealthspire Advisors LLC grew its stake in Pfizer by 21.4% during the 3rd quarter. Wealthspire Advisors LLC now owns 150,164 shares of the biopharmaceutical company’s stock valued at $4,981,000 after purchasing an additional 26,455 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PFE shares. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Shares of PFE stock traded up $0.04 during trading hours on Monday, reaching $25.90. The company had a trading volume of 35,623,531 shares, compared to its average volume of 42,737,133. The company has a market capitalization of $146.66 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $41.33. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a fifty day moving average of $27.28 and a 200-day moving average of $28.88.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.14 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.